European Journal of Cancer Prevention最新文献

{"title":"Cardiovascular death risk in patients with solid tumors: a population-based study in the United States.","authors":"Shuaijie Gao, Hao Zhu, Xinyu Chang, Xiting Cao, Zhenwei Wang, Xiaoxuan Chu, Lu Zhang, Xinhua Wang, Jie Lu","doi":"10.1097/CEJ.0000000000000921","DOIUrl":"10.1097/CEJ.0000000000000921","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have focused on the risk of cardiovascular disease (CVD)-specific death in hematological cancers and in some single anatomical tumor sites, there remains a paucity of data on systematic analyses in solid tumors.</p><p><strong>Objective: </strong>The objective of this study is to evaluate the distribution, risk, and trends of CVD-specific death in patients with solid tumors.</p><p><strong>Methods: </strong>A total of 2 679 293 patients with solid tumors diagnosed between 1975 and 2019 were screened from the Surveillance, Epidemiology and End Results (SEER) program across 15 anatomical sites. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were used to describe the intensity of CVD-specific death, competing risk regression models were used to assess the risk of CVD-specific death, and restricted cubic spline analyses were employed to investigate the potential linear or nonlinear relationship between age and CVD death.</p><p><strong>Results: </strong>CVD-specific death in patients with solid tumors accounted for 48.95% of non-cancer deaths. Compared with the general population, patients with solid tumors had higher SMR and AER of CVD death (SMR: 1.15; AER: 21.12), heart disease-related death (SMR: 1.13; AER: 13.96), and cerebrovascular disease-related death (SMR: 1.20; AER: 4.85). Additionally, the SMR exhibited a decreasing trend with increasing time to diagnosis. Furthermore, a nonlinear relationship was observed between age and CVD-specific death in patients with solid tumors of different systems.</p><p><strong>Conclusion: </strong>CVD-specific death accounted for a large proportion of the cause of non-cancer deaths. Patients with solid tumors exhibit an elevated risk of CVD-specific death. Screening for CVD death and optimizing risk management in patients with solid tumors throughout anticancer treatment may be beneficial in preventing CVD death.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"11-23"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring breast cancer screening fear through a psychosocial lens.","authors":"Vikas Burugu, Mary Salvatore","doi":"10.1097/CEJ.0000000000000895","DOIUrl":"10.1097/CEJ.0000000000000895","url":null,"abstract":"<p><p>Breast cancer screening is crucial for early detection and treatment. Yet, underutilization persists due to various psychosocial factors. This manuscript delves into the multifaceted fears that hinder screening adherence. The literature provides a framework categorizing breast cancer screening fears into generalized cancer fear, fear of screening components, and fear of screening outcomes. In this review, we explore fear of screening components (concerns regarding radiation, discomfort, and pain) and fear of screening outcomes (disability and mortality apprehension, treatment fears, obligation anxiety, and financial concerns) as undesirable, and potentially addressable, aspects of breast cancer screening fear. False-positive results exacerbate these anxieties, prolonging distress and impacting patients' lives beyond the screening process. Addressing these concerns requires reframing current screening approaches to prioritize patient comfort, cultural sensitivity, and accessibility. To address current psychosocial challenges in breast cancer screening, this manuscript advocates for modifying breast cancer screening methods to improve adherence and patient well-being.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"76-80"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between birth weight and risk of nonneurological childhood cancers: a systematic review and meta-analysis.","authors":"Roya Rashti, Faezeh Ghasemi, Jalal Poorolajal","doi":"10.1097/CEJ.0000000000000894","DOIUrl":"10.1097/CEJ.0000000000000894","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review aims to synthesize the available literature to determine the association between birthweight and the risk of nonneurological childhood cancers.</p><p><strong>Methods: </strong>We conducted a systematic search of PubMed, Web of Science, and Scopus databases up to May 2023 to identify observational studies. Heterogeneity between studies was evaluated using the I2 statistics. Publication bias was assessed using Begg and Egger tests. We calculated the odds ratio (OR) or risk ratio (RR) with a 95% confidence interval (CI) using a random-effects model.</p><p><strong>Results: </strong>Of 11 034 studies retrieved from the search, 56 studies (including 10 568 091 participants) were eligible. The ORs (95% CI) of low (<2500 g) versus normal birthweight (2500-4000 g) and childhood cancers were as follows: leukemia, 0.92 (0.77-1.11); acute lymphoblastic leukemia, 0.82 (0.72-0.94); acute myeloid leukemia, 0.98 (0.77-1.24); lymphoma, 0.99 (0.47-2.10); Hodgkin, 0.79 (0.61-1.03); non-Hodgkin, 0.85 (0.60-1.20); neuroblastoma, 1.34 (1.14-1.58); retinoblastoma, 0.95 (0.68-1.32); rhabdomyosarcoma, 0.86 (0.61-1.20); embryonal, 0.97 (0.66-1.43); alveolar, 1.92 (0.43-8.51); and Wilms tumor, 1.01 (0.83-1.24). The ORs (95% CI) of high (>4000 g) versus normal birthweight and childhood cancers were as follows: leukemia, 1.30 (1.18-1.42); acute lymphoblastic leukemia, 1.27 (1.16-1.39); acute myeloid leukemia, 1.13 (0.98-1.30); lymphoma, 1.69 (0.72-3.94); Hodgkin, 1.22 (1.02-1.46); non-Hodgkin, 1.22 (0.80-1.86); neuroblastoma, 1.20 (1.02-1.41); retinoblastoma, 1.17 (0.93-1.48); rhabdomyosarcoma, 1.07 (0.90-1.27); embryonal, 1.22 (1.00-1.49); alveolar, 1.02 (0.46-2.27); and Wilms tumor, 1.49 (1.34-1.67).</p><p><strong>Conclusion: </strong>This meta-analysis identified high birth weight as a potential risk factor for some childhood cancers, while low birth weight might be protective against a few.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"40-52"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent trends in the incidence of early-onset prostate cancer.","authors":"Yanjun Zheng, Jinshui Mao, Lina Yang, Qiansan Zhu","doi":"10.1097/CEJ.0000000000000897","DOIUrl":"10.1097/CEJ.0000000000000897","url":null,"abstract":"<p><p>Early-onset prostate cancer (EOPC) is relatively uncommon. It is unclear if the incidence of EOPC is evolving. Utilizing data from the SEER database from 2000 to 2020, the study identified prostate cancer cases in men under 55 years, focusing on trends in annual age-adjusted incidence rates (AAIR), stage at presentation, race/ethnicity, and local treatment patterns. The study encompassed 93 071 cases of EOPC, with the median age at diagnosis being 51 years. From 2000 to 2007, the AAIR of EOPC experienced a wave-like increase from 6.9 to 8.3 per 100 000 people. It then sharply declined to 5.4 by 2014, followed by 6 years of stability, and by 2020 it had dropped to its lowest point of 4.5. The trend observed across different racial groups was consistent with the overall pattern, where non-Hispanic Black patients consistently exhibited the highest incidence and the least reduction rate (annual percent change, -1.0; 95% confidence interval, -1.8 to -0.2; P  < 0.05). Stage II was the most commonly diagnosed, although its AAIR declined from 4.9 to 1.2 per 100 000 people. From 2010 through 2020, the proportion of receiving prostatectomy decreased from 63.0 to 43.6%. The declining rates of EOPC across diverse racial groups emphasize the critical need for focused research and interventions. Specifically, there is an urgent call to establish a tailored screening protocol for prostate cancer targeting Black youth.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"89-95"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of ovarian cancer among young women during 1990-2019.","authors":"Qingyuan Zhuang, Gaocheng Gu, Jiyu Chen, Zhuojun Tang, Chenxi Wu, Jiahui Liu, Lili Qu","doi":"10.1097/CEJ.0000000000000899","DOIUrl":"10.1097/CEJ.0000000000000899","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer, the most devastating tumor in women globally, significantly impacts young women, compromising their daily lives and overall well-being. Ovarian cancer represents a significant public health concern due to its extensive physical and psychological consequences.</p><p><strong>Material and methods: </strong>Data from the Global Burden of Disease were used to assess the global, regional, and national burden of ovarian cancer in young women aged 20-39 from 1990 to 2019. This analysis focused on trends measured by the estimated annual percentage change and explored the socioeconomic impacts via the socio-demographic index (SDI).</p><p><strong>Results: </strong>During 1990-2019, the incidence and prevalence of ovarian cancer among young women increased globally, with annual rates of 0.74% and 0.89%, respectively. The mortality rate and disability-adjusted life years also rose annually by 0.20% and 0.23%, respectively. A significant burden shift was observed toward regions with lower SDI, with high fasting plasma glucose, BMI, and asbestos exposure identified as prominent risk factors, particularly in lower SDI regions.</p><p><strong>Conclusion: </strong>Our findings underscore ovarian cancer in young women as an escalating global health challenge, with the burden increasingly shifting toward lower socioeconomic areas. This underscores the necessity for targeted prevention and control strategies for ovarian cancer, focusing on reducing the identified risk factors and ensuring equitable health resource distribution.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of machine learning in the analysis of multiparametric MRI data for the differentiation of treatment responses in breast cancer: retrospective study.","authors":"Jinhua Wang, Liang Wang, Zhongxian Yang, Wanchang Tan, Yubao Liu","doi":"10.1097/CEJ.0000000000000892","DOIUrl":"10.1097/CEJ.0000000000000892","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to develop and validate a multiparametric MRI model employing machine learning to predict the effectiveness of treatment and the stage of breast cancer.</p><p><strong>Methods: </strong>The study encompassed 400 female patients diagnosed with breast cancer, with 200 individuals allocated to both the control and experimental groups, undergoing examinations in Shenzhen, China, during the period 2017-2023. This study pertains to retrospective research. Multiparametric MRI was employed to extract data concerning tumor size, blood flow, and metabolism.</p><p><strong>Results: </strong>The model achieved high accuracy, predicting treatment outcomes with an accuracy of 92%, sensitivity of 88%, and specificity of 95%. The model effectively classified breast cancer stages: stage I, 38% ( P  = 0.027); stage II, 72% ( P  = 0.014); stage III, 50% ( P  = 0.032); and stage IV, 45% ( P  = 0.041).</p><p><strong>Conclusions: </strong>The developed model, utilizing multiparametric MRI and machine learning, exhibits high accuracy in predicting the effectiveness of treatment and breast cancer staging. These findings affirm the model's potential to enhance treatment strategies and personalize approaches for patients diagnosed with breast cancer. Our study presents an innovative approach to the diagnosis and treatment of breast cancer, integrating MRI data with machine learning algorithms. We demonstrate that the developed model exhibits high accuracy in predicting treatment efficacy and differentiating cancer stages. This underscores the importance of utilizing MRI and machine learning algorithms to enhance the diagnosis and individualization of treatment for this disease.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"56-65"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the threat of malignant melanoma in the UK still increasing? A comprehensive analysis of 30 years of historical data and Bayesian age-period-cohort model projections for 2030.","authors":"Hao Chen, Yangyang Wang","doi":"10.1097/CEJ.0000000000000947","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000947","url":null,"abstract":"<p><p>Malignant melanoma, a highly aggressive skin cancer, though less common, significantly contributes to cancer-related mortality. In the UK, it is of growing concern with an aging population, making it crucial to analyze historical trends and forecast future burdens. We used Joinpoint regression and age-period-cohort models to analyze trends in incidence, prevalence, and mortality of malignant melanoma in the UK from 1990 to 2021. Bayesian age-period-cohort model was applied to predict the disease burden for different age groups by 2030. From 1991 to 2021, melanoma incidence and prevalence in the UK exhibited distinct temporal patterns: a significant upward trend until 2015, particularly pronounced in individuals aged 60 and older, followed by a downward trend after 2015. By 2030, incidence and prevalence are projected to decrease, particularly in younger and middle-aged populations, with incidence expected to fall from 20.78/100 000 in 2020 to 11.90/100 000, and prevalence from 167.80/100 000 to 80.13/100 000. Mortality is also expected to decrease. However, high-risk groups, especially those aged 85 and above, are predicted to maintain higher incidence and prevalence rates. Despite a historical rise, melanoma incidence, prevalence, and mortality have declined since 2015 and are projected to continue declining through 2030. However, the elderly population remains at higher risk, underscoring the need for targeted public health interventions.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between weight loss and survival outcomes in patients with gastric cancer: a meta-analysis.","authors":"Heng Zhang, Xuan Tang, Junfang Zhang, Dapeng Jiang, Dandan Gong, Yu Fan","doi":"10.1097/CEJ.0000000000000946","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000946","url":null,"abstract":"<p><p>Patients with gastric cancer often experience weight loss. A meta-analysis was conducted to evaluate the association between weight loss and survival outcomes in gastric cancer patients. We searched PubMed, Embase, and Web of Science according to the PECOS criteria: population (gastric cancer patients), exposure (weight loss), comparator (weight stable), outcomes [overall survival (OS) or recurrence-free survival], and study design (cohort studies). The prognostic value was expressed by combing the fully adjusted hazard ratio with 95% confidence interval (CI) for weight loss versus stable weight. Eighteen studies reporting on 16 articles involving 26 080 patients were identified. The pooled adjusted relative risk showed that weight loss was associated with shorter OS (hazard ratio 1.48; 95% CI: 1.32-1.66; I2 = 71.0%) and recurrence-free survival (hazard ratio 1.59; 95% CI: 1.17-2.16; I2 = 52.0%). The pooled adjusted hazard ratio of OS was 1.39 (95% CI: 1.14-1.70; I2 = 74.6%) among the studies that defined weight loss meeting the criteria for cancer cachexia. Moreover, stratified analysis revealed that weight loss significantly predicted OS, irrespective of patients' age, study design, tumor stage, timing of sampling weight loss, or follow-up duration. Weight loss significantly predicts OS and recurrence-free survival in gastric cancer patients. Monitoring weight changes can improve risk classification of gastric cancer, particularly in those with advanced disease.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Old age decreases the risk of lymph node metastasis in T1-2 hypopharynx squamous cell carcinoma patients.","authors":"Yujiao Li, Chaosu Hu","doi":"10.1097/CEJ.0000000000000945","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000945","url":null,"abstract":"<p><p>Cervical lymph node metastasis (LNM) is an important prognostic factor for hypopharynx squamous cell carcinoma (SCC) patients, which can be detected in a large fraction of clinically diagnosed early hypopharynx SCC patients; however, the importance of knowing the risk of LNM in the younger/older patients has not been well defined. The objective of this study is to assess the effect of age and LNM in T1-2 hypopharynx SCC patients. Patients with T1-2 hypopharynx SCC were extracted from the Surveillance, Epidemiology and End Results database between 2005 and 2014. Univariate and multivariate logistic regression models were produced to recognize the association between age and risk factors of LNM. A total of 1018 patients were analyzed. Older patients have a lower risk of LNM compared with their younger peers (P < 0.01). In multivariate analyses, older age was associated with a significantly lower risk of LNM. Compared with patients aged 80-93 years old, the hazard ratios for patients aged 31-49, 50-59, 60-69, and 70-79 years old were 2.464 [95% confidence interval (CI): 1.338-4.537], 2.668 (95% CI: 1.638-4.346), 3.192 (95% CI: 1.957-5.205), and 1.564 (95% CI: 0.945-2.588), respectively. Subgroup analysis shows that the effect of older age was significantly associated with a higher risk of LNM in Caucasian male who harbored moderately/poorly differentiated tumors. Our study demonstrates that older patients with T1-2 hypopharynx SCC had a lower risk of LNM than their younger peers, especially males with moderately/poorly differentiated tumors. More accurate assessments of LNM and prophylactic neck dissection or prophylactic adjuvant radiation therapy to the neck will be imperative for reducing recurrence in younger T1-2 hypopharynx SCC.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis.","authors":"Sirui Zhang, Elizabeth Maria Kappil, Tongzhang Zheng, Paolo Boffetta, Monireh Sadat Seyyedsalehi","doi":"10.1097/CEJ.0000000000000935","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000935","url":null,"abstract":"<p><strong>Background: </strong>Per- and poly-fluoroalkyl substances (PFASs) are a group of synthetic chemicals used since the 1940s in industrial and consumer applications. These substances are known or suspected to cause cancer, particularly kidney and testicular cancer. However, their association with other types of cancer is not well understood. This review aims to investigate the link between PFAS exposure and the risks of other cancers, including gastrointestinal cancers such as esophageal, gastric, colorectal, and pancreatic cancer.</p><p><strong>Methods: </strong>We conducted a systematic review of literature from the International Agency for Research on Cancer Monographs, Agency for Toxic Substances and Disease Registry documents, and PubMed (up to January 2024) focusing on the association between PFAS exposure and gastrointestinal cancers. Four independent reviewers screened the studies, extracted the information, and evaluated the quality of the studies using a modified Newcastle-Ottawa Scale. Meta-analyses were performed with random-effects models, including stratified analyses and dose-response assessments.</p><p><strong>Results: </strong>The meta-analysis included 17 studies. The summary relative risks (RR) of esophageal cancer for perfluorooctanoic acid (PFOA) exposure was 0.75 (95% confidence interval [CI], 0.35-1.60; n = 2), and for perfluorooctane sulfonic acid (PFOS) was 1.76 (95% CI, 0.32-9.68; n = 1). The RR for gastric cancer and PFOA was 0.59 (95% CI, 0.28-1.21; n = 2) and PFAS was 0.96 (95% CI, 0.83-1.12; n = 2). The RR for colorectal cancer and PFOA was 0.83 (95% CI, 0.65-1.06; n = 6) and PFOS was 0.71 (95% CI, 0.22-2.27; n = 4). The RR for pancreatic cancer was 1.02 (95% CI, 0.90-1.15; n = 9) and PFOS was 0.92 (95% CI, 0.76-1.11; n = 2). Stratified analyses by geographical region, study design, quality score, year of publication, gender, and outcome revealed no associations for colorectal and pancreatic cancers. No dose-response trends were identified. Publication bias was suggested for gastric cancer.</p><p><strong>Conclusion: </strong>Our study suggested no association between PFAS exposure and esophageal, gastric, colorectal, or pancreatic cancer. More rigorous research is needed to investigate this relationship in different settings, with precise PFAS quantification, a wider range of compounds, larger sample sizes for specific cancers, and better control for potential confounders. Our meta-analysis suggests inconclusive evidence, highlighting the need for further research.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}